Checking Early Treatment Options for Patients with High-Risk CLL or SLL

Recruiting · Phase 3 · Chronic Lymphocytic Leukemia and related conditions · 43 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at two ways to treat people with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). One group gets treatment right away with two medicines called venetoclax and obinutuzumab. The other group waits to start treatment until they show symptoms. The goal is to see if starting treatment early helps patients live longer and have better health outcomes.

The trial's ID number is NCT04269902. It is a Phase 3 study, which means it is looking at how well the treatment works and how safe it is. The trial is FDA-regulated and hopes to include around 247 participants.

Who can join

Adults aged 18 and older can join if they have been diagnosed with CLL or SLL within the last 18 months. They should have a specific score that shows their cancer is high-risk. The trial is open to both men and women. The trial team will check if participants meet all the criteria before they join.

Conditions

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be placed into two groups by chance. One group will start treatment right away with venetoclax and obinutuzumab. The other group will wait to begin treatment until they have symptoms. Everyone will receive the same medicines, but the timing is different. They will also have tests like blood samples and scans during the study.